Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and markets brand-name and generic pharmaceuticals and cell therapy platforms for cancer patients. The company is headquartered in Wexford, Pennsylvania.
| Revenue (TTM) | $1.36M |
| Gross Profit (TTM) | $1.18M |
| EBITDA | $-11.86M |
| Operating Margin | -230.70% |
| Return on Equity | -136.90% |
| Return on Assets | -65.10% |
| Revenue/Share (TTM) | $0.32 |
| Book Value | $2.36 |
| Price-to-Book | 5.78 |
| Price-to-Sales (TTM) | 57.62 |
| EV/Revenue | 53.07 |
| EV/EBITDA | -0.64 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1564.00% |
| Shares Outstanding | $6.22M |
| Float | $5.25M |
| % Insiders | 13.72% |
| % Institutions | 9.00% |
Volatility is currently expanding